Ad is loading...
CRSP
Price
$55.06
Change
+$3.89 (+7.60%)
Updated
Dec 2, 04:26 PM (EDT)
78 days until earnings call
PGEN
Price
$0.92
Change
-$0.01 (-1.08%)
Updated
Dec 2, 11:51 AM (EDT)
86 days until earnings call
Ad is loading...

CRSP vs PGEN

Header iconCRSP vs PGEN Comparison
Open Charts CRSP vs PGENBanner chart's image
CRISPR Therapeutics AG
Price$55.06
Change+$3.89 (+7.60%)
Volume$3.38K
CapitalizationN/A
Precigen
Price$0.92
Change-$0.01 (-1.08%)
Volume$600
CapitalizationN/A
CRSP vs PGEN Comparison Chart
Loading...
CRSP
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
PGEN
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
View a ticker or compare two or three
VS
CRSP vs. PGEN commentary
Dec 02, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRSP is a Hold and PGEN is a Hold.

COMPARISON
Comparison
Dec 02, 2024
Stock price -- (CRSP: $51.17 vs. PGEN: $0.93)
Brand notoriety: CRSP and PGEN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CRSP: 54% vs. PGEN: 50%
Market capitalization -- CRSP: $4.37B vs. PGEN: $272.98M
CRSP [@Biotechnology] is valued at $4.37B. PGEN’s [@Biotechnology] market capitalization is $272.98M. The market cap for tickers in the [@Biotechnology] industry ranges from $476.43B to $0. The average market capitalization across the [@Biotechnology] industry is $2.7B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRSP’s FA Score shows that 0 FA rating(s) are green whilePGEN’s FA Score has 0 green FA rating(s).

  • CRSP’s FA Score: 0 green, 5 red.
  • PGEN’s FA Score: 0 green, 5 red.
According to our system of comparison, both CRSP and PGEN are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRSP’s TA Score shows that 6 TA indicator(s) are bullish while PGEN’s TA Score has 6 bullish TA indicator(s).

  • CRSP’s TA Score: 6 bullish, 4 bearish.
  • PGEN’s TA Score: 6 bullish, 3 bearish.
According to our system of comparison, PGEN is a better buy in the short-term than CRSP.

Price Growth

CRSP (@Biotechnology) experienced а +6.87% price change this week, while PGEN (@Biotechnology) price change was +3.27% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.63%. For the same industry, the average monthly price growth was +2.65%, and the average quarterly price growth was +11.60%.

Reported Earning Dates

CRSP is expected to report earnings on Feb 18, 2025.

PGEN is expected to report earnings on Feb 26, 2025.

Industries' Descriptions

@Biotechnology (+4.63% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CRSP($4.37B) has a higher market cap than PGEN($273M). CRSP YTD gains are higher at: -18.259 vs. PGEN (-30.440). PGEN has higher annual earnings (EBITDA): -136.11M vs. CRSP (-313.08M). CRSP has more cash in the bank: 1.94B vs. PGEN (28.6M). PGEN has less debt than CRSP: PGEN (5.75M) vs CRSP (228M). CRSP has higher revenues than PGEN: CRSP (200M) vs PGEN (3.96M).
CRSPPGENCRSP / PGEN
Capitalization4.37B273M1,600%
EBITDA-313.08M-136.11M230%
Gain YTD-18.259-30.44060%
P/E RatioN/AN/A-
Revenue200M3.96M5,047%
Total Cash1.94B28.6M6,769%
Total Debt228M5.75M3,966%
FUNDAMENTALS RATINGS
CRSP vs PGEN: Fundamental Ratings
CRSP
PGEN
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
63
Fair valued
57
Fair valued
PROFIT vs RISK RATING
1..100
97100
SMR RATING
1..100
9398
PRICE GROWTH RATING
1..100
5561
P/E GROWTH RATING
1..100
86100
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PGEN's Valuation (57) in the null industry is in the same range as CRSP (63) in the Biotechnology industry. This means that PGEN’s stock grew similarly to CRSP’s over the last 12 months.

CRSP's Profit vs Risk Rating (97) in the Biotechnology industry is in the same range as PGEN (100) in the null industry. This means that CRSP’s stock grew similarly to PGEN’s over the last 12 months.

CRSP's SMR Rating (93) in the Biotechnology industry is in the same range as PGEN (98) in the null industry. This means that CRSP’s stock grew similarly to PGEN’s over the last 12 months.

CRSP's Price Growth Rating (55) in the Biotechnology industry is in the same range as PGEN (61) in the null industry. This means that CRSP’s stock grew similarly to PGEN’s over the last 12 months.

CRSP's P/E Growth Rating (86) in the Biotechnology industry is in the same range as PGEN (100) in the null industry. This means that CRSP’s stock grew similarly to PGEN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CRSPPGEN
RSI
ODDS (%)
Bearish Trend 4 days ago
74%
Bearish Trend 4 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 4 days ago
89%
Bullish Trend 4 days ago
86%
Momentum
ODDS (%)
Bullish Trend 4 days ago
78%
Bullish Trend 4 days ago
89%
MACD
ODDS (%)
Bullish Trend 4 days ago
82%
Bullish Trend 4 days ago
78%
TrendWeek
ODDS (%)
Bullish Trend 4 days ago
76%
Bullish Trend 4 days ago
85%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
79%
Bullish Trend 4 days ago
84%
Advances
ODDS (%)
Bullish Trend 4 days ago
81%
Bullish Trend 4 days ago
83%
Declines
ODDS (%)
Bearish Trend 19 days ago
85%
Bearish Trend 15 days ago
86%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
75%
Bullish Trend 4 days ago
86%
Aroon
ODDS (%)
Bullish Trend 4 days ago
77%
Bearish Trend 4 days ago
90%
View a ticker or compare two or three
Ad is loading...
CRSP
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
PGEN
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GSTRX10.250.09
+0.89%
Goldman Sachs Strategic Growth R
EIDIX17.300.12
+0.70%
Eaton Vance Global Equity Income I
WASAX23.110.12
+0.52%
Delaware Ivy Asset Strategy Fund Cl A
DTSGX18.470.07
+0.38%
Wilshire Small Company Growth Invmt
TWEIX9.680.02
+0.21%
American Century Equity Income Inv

CRSP and

Correlation & Price change

A.I.dvisor indicates that over the last year, CRSP has been closely correlated with BEAM. These tickers have moved in lockstep 74% of the time. This A.I.-generated data suggests there is a high statistical probability that if CRSP jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRSP
1D Price
Change %
CRSP100%
+0.65%
BEAM - CRSP
74%
Closely correlated
+0.63%
NTLA - CRSP
61%
Loosely correlated
+2.70%
EDIT - CRSP
61%
Loosely correlated
+1.82%
PRME - CRSP
60%
Loosely correlated
-0.30%
RXRX - CRSP
58%
Loosely correlated
+10.82%
More

PGEN and

Correlation & Price change

A.I.dvisor indicates that over the last year, PGEN has been loosely correlated with CRSP. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if PGEN jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PGEN
1D Price
Change %
PGEN100%
+2.50%
CRSP - PGEN
54%
Loosely correlated
+0.65%
BEAM - PGEN
52%
Loosely correlated
+0.63%
NTLA - PGEN
52%
Loosely correlated
+2.70%
RCKT - PGEN
50%
Loosely correlated
+1.34%
DNLI - PGEN
50%
Loosely correlated
-0.64%
More